BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rentsch V, Seipel K, Banz Y, Wiedemann G, Porret N, Bacher U, Pabst T. Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. Cancers 2022;14:2516. [DOI: 10.3390/cancers14102516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Wittibschlager V, Bacher U, Seipel K, Porret N, Wiedemann G, Haslebacher C, Hoffmann M, Daskalakis M, Akhoundova D, Pabst T. CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma. IJMS 2023;24:5688. [DOI: 10.3390/ijms24065688] [Reference Citation Analysis]
2 Lakomy T, Akhoundova D, Nilius H, Kronig MN, Novak U, Daskalakis M, Bacher U, Pabst T. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome. Biomolecules 2023;13. [PMID: 36830750 DOI: 10.3390/biom13020382] [Reference Citation Analysis]
3 Del Toro-Mijares R, Oluwole O, Jayani RV, Kassim AA, Savani BN, Dholaria B. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options. Br J Haematol 2023. [PMID: 36709623 DOI: 10.1111/bjh.18656] [Reference Citation Analysis]
4 Heini AD, Bacher U, Porret N, Wiedemann G, Legros M, Stalder Zeerleder D, Seipel K, Novak U, Daskalakis M, Pabst T. Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma. Cells 2022;11:2747. [PMID: 36078155 DOI: 10.3390/cells11172747] [Reference Citation Analysis]